Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

Збережено в:

Бібліографічні деталі
Автор:	Vishwajith Sridharan (15047154) (author)
Інші автори:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
Опубліковано:	2025
Предмети:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
за авторством: Jiachun Su (16990970)
Опубліковано: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
за авторством: Joel R. Eisner (15132120)
Опубліковано: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
за авторством: Joel R. Eisner (15132120)
Опубліковано: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
за авторством: Joel R. Eisner (15132120)
Опубліковано: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
за авторством: Nicholas T. Younger (14956251)
Опубліковано: (2025)

Genetic variation and mRNA expression of the <i>ELOVL6</i> and <i>CRTC2</i> genes in Kalmyk cattle
за авторством: Nurlybay Kazhgaliyev (9904228)
Опубліковано: (2025)

APP deficiency did not affect the mRNA level of <i>Scn8a</i> in cerebellar PCs.
за авторством: Miao-Jin Ji (22676552)
Опубліковано: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
за авторством: Natalie C. Fisher (15046025)
Опубліковано: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
за авторством: Natalie C. Fisher (15046025)
Опубліковано: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
за авторством: Natalie C. Fisher (15046025)
Опубліковано: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
за авторством: Natalie C. Fisher (15046025)
Опубліковано: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
за авторством: Natalie C. Fisher (15046025)
Опубліковано: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
за авторством: Natalie C. Fisher (15046025)
Опубліковано: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
за авторством: Carlotta Antoniotti (15352506)
Опубліковано: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
за авторством: Carlotta Antoniotti (15352506)
Опубліковано: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
за авторством: Carlotta Antoniotti (15352506)
Опубліковано: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
за авторством: Katie E. Hebron (15046889)
Опубліковано: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
за авторством: Ruth Flümann (15123900)
Опубліковано: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
за авторством: Ruth Flümann (15123900)
Опубліковано: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
за авторством: Ruth Flümann (15123900)
Опубліковано: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
за авторством: Ruth Flümann (15123900)
Опубліковано: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
за авторством: Ruth Flümann (15123900)
Опубліковано: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
за авторством: Ruth Flümann (15123900)
Опубліковано: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_105fplepogcm0lh6eb177l7ebp